Study of Split-course Chemoradiotherapy For Postoperative Locoregional Recurrence Of Non-small Cell Lung Cancer

Inclusion Criteria

• •Pathologic confirmation of NSCLC.
• •Patients have measurable or evaluable lesions based on the Response Evaluation Criteria in Solid Tumors (RECIST) criteria.
• •Postoperative locoregional recurrence including ipsilateral hemithorax and the mediastinum.
• •Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
• •Previously treated with chemotherapy or treatment-naive
• •No previous chest radiotherapy, immunotherapy or biotherapy
• •Hemoglobin≥10 mg/dL, platelet≥100000/μL,absolute neutrophil count ≥1500/μL
• •Serum creatinine ≤1.25 times the upper normal limit(UNL), or creatinine clearance≥60 ml/min
• •Bilirubin ≤1.5 times UNL, AST（SGOT）≤2.5 times UNL ,ALT（SGPT）≤2.5 times UNL,alkaline phosphatase ≤5 times UNL
• •Forced expiratory volume at one second (FEV1) \>0.8 L
• •Coagulation tests within normal limits
• •patients and their family signed the informed consents